Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0M8PM
|
|||
Former ID |
DIB003356
|
|||
Drug Name |
IRX-4
|
|||
Synonyms |
IRX-2 + tumor-specific antigen (cancer), IRx Therapeutics
Click to Show/Hide
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Preclinical | [1] | |
Company |
IRX Therapeutics Inc
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glutamate carboxypeptidase II (GCPII) | Target Info | Immunomodulator (Immunostimulant) | [2] |
KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
Metabolic pathways | ||||
Vitamin digestion and absorption | ||||
NetPath Pathway | TCR Signaling Pathway | |||
TNFalpha Signaling Pathway | ||||
Reactome | Amino acid synthesis and interconversion (transamination) | |||
WikiPathways | One Carbon Metabolism |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026363) | |||
REF 2 | Irx4 identifies a chamber-specific cell population that contributes to ventricular myocardium development. Dev Dyn. 2014 Mar;243(3):381-92. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.